Psoriasis has been lately seen as a potential systemic inflammatory disease associated with a range of comorbidities exhibiting an overlapping pathology and presenting a great social health impact such as cardiovascular disease and metabolic diseases,including obesity.Adipose tissue is considered a genuine endocrine organ producing a variety of bioactive adipocytokines,like leptin,adiponectin,resistin and visfatin,participating in physiological and pathological processes,such as energy balance,insulin sensitivity and resistance,immunity,inflammation,hematopoiesis and angiogenesis.Adipocytokines could serve as a missing link in the association between psoriasis,obesity and metabolic co-morbidities.In chronic inflammatory disease states such as psoriasis,adipocytokines may be implicated in psoriasis onset,progression,severity as well as in the pathogenesis of co-morbidities.Measuring serum adipocytokine levels in the future may be useful in predicting psoriasis severity,progression,treatment outcome and risk of any co-morbidities.Interventions to decrease pro-inflammatory adipocytokine levels could offer preventive and therapeutic options for improving psoriasis severity and protecting against its co-morbidities.Candidate strategic interventions incorporate increased physical activity,weight control and pharmacologic approaches such as metformin.However,the mechanisms underlying the actions of adipocytokines in psoriasis as well as their potential diagnostic,prognostic and/or therapeutic utility require further investigation with larger prospective,longitudinal and mechanistic studies.